These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 1974288)

  • 1. Evidence for more than one binding site for sulfonylureas in insulin-secreting cells.
    Verspohl EJ; Ammon HP; Mark M
    J Pharm Pharmacol; 1990 Apr; 42(4):230-5. PubMed ID: 1974288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Control of insulin secretion by sulfonylureas, meglitinide and diazoxide in relation to their binding to the sulfonylurea receptor in pancreatic islets.
    Panten U; Burgfeld J; Goerke F; Rennicke M; Schwanstecher M; Wallasch A; Zünkler BJ; Lenzen S
    Biochem Pharmacol; 1989 Apr; 38(8):1217-29. PubMed ID: 2650685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction of fluorescein derivatives with sulfonylurea binding in insulin-secreting cells.
    Schwanstecher M; Bachmann C; Löser S; Panten U
    Pharmacology; 1995 Mar; 50(3):182-91. PubMed ID: 7746835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucose modulates the amount, but not the kinetics, of insulin released by sulfonylureas.
    Gregorio F; Ambrosi F; Filipponi P; Cristallini S; Santeusanio F
    J Diabetes Complications; 1994; 8(4):204-12. PubMed ID: 7833495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential interaction of glimepiride and glibenclamide with the beta-cell sulfonylurea receptor. II. Photoaffinity labeling of a 65 kDa protein by [3H]glimepiride.
    Kramer W; Müller G; Girbig F; Gutjahr U; Kowalewski S; Hartz D; Summ HD
    Biochim Biophys Acta; 1994 May; 1191(2):278-90. PubMed ID: 8172913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of the molecular mode of action of the sulfonylurea, glimepiride, at beta-cells.
    Kramer W; Müller G; Geisen K
    Horm Metab Res; 1996 Sep; 28(9):464-8. PubMed ID: 8911984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes.
    Fuhlendorff J; Rorsman P; Kofod H; Brand CL; Rolin B; MacKay P; Shymko R; Carr RD
    Diabetes; 1998 Mar; 47(3):345-51. PubMed ID: 9519738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pancreatic beta-cell K(ATP) channel activity and membrane-binding studies with nateglinide: A comparison with sulfonylureas and repaglinide.
    Hu S; Wang S; Fanelli B; Bell PA; Dunning BE; Geisse S; Schmitz R; Boettcher BR
    J Pharmacol Exp Ther; 2000 May; 293(2):444-52. PubMed ID: 10773014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological characterization of the sulphonylurea receptor in rat isolated aorta.
    Löffler C; Quast U
    Br J Pharmacol; 1997 Feb; 120(3):476-80. PubMed ID: 9031752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two binding sites for [3H]glibenclamide in the rat brain.
    Zini S; Tremblay E; Roisin MP; Ben-Ari Y
    Brain Res; 1991 Feb; 542(1):151-4. PubMed ID: 1905178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sulphonylurea binding in rat isolated glomeruli: pharmacological characterization and dependence on cell metabolism and cytoskeleton.
    Metzger F; Löffler C; Quast U
    Naunyn Schmiedebergs Arch Pharmacol; 1997 Feb; 355(2):141-9. PubMed ID: 9050005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of K+ channels and stimulation of insulin secretion by the sulfonylurea, glimepiride, in relation to its membrane binding in pancreatic islets.
    Schwanstecher M; Mnner K; Panten U
    Pharmacology; 1994 Aug; 49(2):105-11. PubMed ID: 7972319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The insulin-secreting and proliferative activity of established islet cells in the presence of sulfonylurea].
    Balabolkin MI; Timofeev AV; Danilova TI; Zhuleva LIu; Ol'shanskaia AA
    Biull Eksp Biol Med; 1992 Oct; 114(10):406-8. PubMed ID: 1288706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of gliquidone action by forskolin in the pancreas of normal and GK rats.
    Leclercq-Meyer V; Malaisse WJ
    Am J Physiol; 1997 Jul; 273(1 Pt 1):E52-8. PubMed ID: 9252479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of sulfonylurea receptors and the action of potassium channel openers on cholinergic neurotransmission in guinea pig isolated small intestine.
    Zini S; Ben-Ari Y; Ashford ML
    J Pharmacol Exp Ther; 1991 Nov; 259(2):566-73. PubMed ID: 1658303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of 3H-glibenclamide binding to sulfonylurea receptors by oral antidiabetics.
    Geisen K; Hitzel V; Okomonopoulos R; Pünter J; Weyer R; Summ HD
    Arzneimittelforschung; 1985; 35(4):707-12. PubMed ID: 3925960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of low-affinity binding sites for glibenclamide on the Kir6.2 subunit of the beta-cell KATP channel.
    Gros L; Virsolvy A; Salazar G; Bataille D; Blache P
    Biochem Biophys Res Commun; 1999 Apr; 257(3):766-70. PubMed ID: 10208857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glibenclamide and gliquidone in the treatment of non-insulin-dependent diabetes mellitus.
    Nikkilä K; Groop L
    Acta Med Scand; 1982; 211(1-2):13-7. PubMed ID: 6803519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effect of gliquidone and glibenclamide following oral administration].
    Ziler T; Waldthaler A; Ermler R; Bottermann P
    MMW Munch Med Wochenschr; 1975 Sep; 117(36):1423-4. PubMed ID: 809687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The receptor for antidiabetic sulfonylureas controls the activity of the ATP-modulated K+ channel in insulin-secreting cells.
    Schmid-Antomarchi H; De Weille J; Fosset M; Lazdunski M
    J Biol Chem; 1987 Nov; 262(33):15840-4. PubMed ID: 2445740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.